Pacific Biosciences faces a critical financial crossroads, with its balance sheet deteriorating into negative equity of -$33.2M and a cash position of only $61.0M against $706.1M in total debt as of 2026Q2.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 4, 2026 | -$0.11+18.2% vs -$0.13 | $41M+3.2% vs $39M |
Q3 2026 Aug 5, 2026 | -$0.14+0.0% vs -$0.14 | $39M-2.3% vs $40M |
Q2 2026 May 7, 2026 | -$0.03+82.4% vs -$0.17 | $37M-6.9% vs $40M |
Q1 2026 Feb 12, 2026 | -$0.12+36.8% vs -$0.19 | $45M+3.7% vs $43M |
MENLO PARK, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be participating in the following upcoming investor conferences:
PACB's growing clinical adoption, advanced sequencing technologies and rising consumables sales support growth, but funding headwinds and margin pressures persist.
The latest trading day saw Pacific Biosciences of California (PACB) settling at $2.06, representing a -3.74% change from its previous close.
Verily Pre will connect PacBio HiFi Sequencing with governed cloud analysis, multimodal health data and AI-ready research workflows Verily Pre will connect PacBio HiFi Sequencing with governed cloud analysis, multimodal health data and AI-ready research workflows
Benchmark PACB against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Pacific Biosciences of California, Inc. (PACB)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.26 | $701.96M | -5.36 | 3.89% | -81.31% | -2618.51% | — | |
| $213.13 | $32.25B | 36.67 | -0.78% | 19.72% | 31.45% | — | |
| $6.37 | $1.7B | -31.61 | 18.96% | -43.56% | -28.22% | — | |
| $78.56 | $4.06B | 33.58 | 13.79% | 25.86% | 34.08% | — | |
| $694.76 | $258.19B | 36.39 | 3.91% | 14.96% | 13.3% | 0.24% | |
| $230.25 | $161.86B | 37.58 | 2.9% | 16.91% | 8.18% | 0.54% |
Pacific Biosciences of California, Inc. (PACB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Pacific Biosciences of California, Inc. (PACB) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 5, 2026·SEC
Jul 9, 2026·SEC
Jun 4, 2026·SEC
Get notified when PACB posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Pacific Biosciences of California, Inc. (PACB) stock FAQ — growth, dividends, profitability & financials explained
Pacific Biosciences of California, Inc. (PACB) reported $161.4M in revenue over the trailing twelve months. Revenue was $160.0M in fiscal year 2025. That is 17659% more than the $0.9M of fiscal year 2008.
Pacific Biosciences of California, Inc. (PACB) grew revenue by 4.4% over the trailing twelve months, compared with the twelve months before.
No. Pacific Biosciences of California, Inc. (PACB) reported a net loss of $131.2M over the trailing twelve months.
Pacific Biosciences of California, Inc. (PACB) had a return on equity (ROE) of -2618.5% over the trailing twelve months. A negative ROE means the company lost money over the period.
Pacific Biosciences of California, Inc. (PACB) had negative free cash flow of $143.4M over the trailing twelve months.
